semaglutide
Wegovy Set for PBS Listing: A New Dawn for Affordable Weight Loss in Australia
Australia’s government plans to subsidize Wegovy under the Pharmaceutical Benefits Scheme (PBS), making the crucial weight-loss medication significantly more affordable for eligible patients with severe obesity and cardiovascular disease. This move could transform access to treatment for thousands, despite potential…
Wegovy Pill Launches: Oral GLP-1 Reshapes Weight Loss Management
Novo Nordisk’s Wegovy pill, the first oral GLP-1 for weight loss, is now broadly available, offering a new, convenient option for millions battling obesity. Learn about its efficacy, cost, and availability.
Novo Nordisk Stock Plunges After Alzheimer’s Trial Failure Spurs Turmoil and Fierce Market Competition
Novo Nordisk’s shares nosedived after its Alzheimer’s drug trial failed, intensifying investor concerns amid fierce competition and strategic shifts. The company faces mounting pressure from rivals, regulatory changes, and leadership upheaval, leaving its future direction under scrutiny.
Semaglutide Shows Promise in Treating Liver Disease MASH
A landmark phase 3 trial reveals semaglutide’s potential to treat metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions globally.